NUSINERSEN

nusinersen 12 mg/5 mL intrathecal injection, 5 mL vial

NUSINERSEN (13111C)

nusinersen 12 mg/5 mL intrathecal injection, 5 mL vial
13111C
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Symptomatic type IIIB/IIIC spinal muscular atrophy (SMA)
Treatment phase: Initial PBS-subsidised treatment in a child

Restriction

Indication: Symptomatic type IIIB/IIIC spinal muscular atrophy (SMA)
Treatment phase: Changing the prescribed therapy
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 3 DPMQ: $104,548.88 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Spinraza